This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Partnering, Business Development & Licensing
search
Drug Development

AmpliPhi advances phage in clinic to address microbial infections

Posted by on 14 July 2017
Share this article

Using cocktails of bacteriophages to attack bacterial infections, San Diego-based AmpliPhi announced progress in Phase I studies of its lead program. Company CEO Scott Salka explains to Mike Ward, Informa Pharma Intelligence’s insights global director of content, how he is looking to secure sufficient capital to support the Phase II development of its lead program against chronic rhinosinusitis while advancing other candidate products.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Scott Salka – CEO, AmpliPhi BioSciences

Share this article

Sign up for Partnering, Business Development & Licensing email updates

keyboard_arrow_down